New Therapeutic Strategies for Type 2 DiabetesCME

Ahmad Yehya; Archana R. Sadhu

doi:10.14797/mdcj-14-4-281

New Therapeutic Strategies for Type 2 DiabetesCME

Methodist DeBakey Cardiovascular Journal

Volume 14 (2018): Issue 4

By: Ahmad Yehya and Archana R. Sadhu

Open Access

|Oct 2018

Abstract

Pharmacological options for treatment of type 2 diabetes (T2D) have advanced rapidly during the last 10 years, allowing clinicians to target different pathophysiological defects in this disease. There are currently 12 different classes of drugs available to treat T2D. The most exciting development is the demonstration of cardiovascular (CV) benefits from two of these new classes, the glucagon-like peptide-1 receptor agonists (GLP-1 RA) and selective sodium glucose transporter 2 (SGLT2) inhibitors. These drugs have challenged conventional algorithms in the management of T2D by exceeding expectations in cardiovascular outcome trials and demonstrating an unexpected reduction in CV events. This review focuses on the physiologic actions and the CV outcomes associated with dipeptidyl peptidase-4 (DPP-4) inhibitor, GLP-1 RA, and SGLT2 inhibitor use. Understanding their potential may revolutionize our approach to the management of T2D.

References

Drucker D Nauck M The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 Nov 11 368 9548 1696 705
Search in Google Scholar Back to article
Holst JJ Orskov C Nielsen OV Schwartz TW Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut FEBS Lett 1987 Jan 26 211 2 169 74
Search in Google Scholar Back to article
Kreymann B Williams G Ghatei MA Bloom SR Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 1987 Dec 5 2 8571 1300 4
Search in Google Scholar Back to article
Mehta A Marso SP Neeland IJ Liraglutide for weight management: a critical review of the evidence Obes Sci Pract 2017 Mar 3 1 3 14
Search in Google Scholar Back to article
Holst JJ Deacon CF Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors Diabetologia 2005 Apr 48 4 612 5
Search in Google Scholar Back to article
Abdul-Ghani MA DeFronzo RA Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus Endocr Pract 2008 Sep 14 6 782 90
Search in Google Scholar Back to article
Nair S Wilding J Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus J Clin Endocrinol Metab 2010 Jan 95 1 34 42
Search in Google Scholar Back to article
Nauck MA Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Drug Des Devel Ther 2014 Sep 11 8 1335 80
Search in Google Scholar Back to article
Mazidi M Rezaie P Gao HK Kengne AP Effect of Sodium-Glucose Cotrans-port-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients J Am Heart Assoc 2017 May 25 6 6
Search in Google Scholar Back to article
U. S. Food and Drug Administration [Internet] Silver Spring, MD U.S. Food and Drug Administration c2018 Guidance for Industry: Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes: 2008 Dec [cited 2018 Aug 2]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
Search in Google Scholar Back to article
Green J Bethel M Armstrong P TECOS Study Group Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2015 Jul 16 373 3 232 42
Search in Google Scholar Back to article
Röhrborn D Wronkowitz N Eckel J DPP4 in Diabetes Front Immunol 2015 Jul 27 6 386
Search in Google Scholar Back to article
Scirica B Bhatt D Braunwald E SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 Oct 3 369 14 1317 26
Search in Google Scholar Back to article
White W Cannon C Heller S EXAMINE Investigators Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 2013 Oct 3 369 14 1327 35
Search in Google Scholar Back to article
Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2010–2018 CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes; 2010 Nov 18 [cited 2018 Jul 2]. Available from: https://clinicaltrials.gov/ct2/show/NCt101243424
Search in Google Scholar Back to article
Pfeffer M Claggett B Diaz R ELIXA Investigators Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome N Engl J Med 2015 Dec 3 373 23 2247 57
Search in Google Scholar Back to article
Marso S Daniels G Brown-Frandsen K LEADER Steering Committee; LEADER Trial Investigators Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2016 Jul 28 375 4 311 22
Search in Google Scholar Back to article
Marso S Bain S Consoli A SUSTAIN-6 Investigators Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med 2016 Nov 10 375 19 1834 44
Search in Google Scholar Back to article
Holman R Bethel M Mentz R Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2017 Sep 28 377 13 1228 39
Search in Google Scholar Back to article
Davies M Bain S Atkin S Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial Diabetes Care 2016 Feb 39 2 222 30
Search in Google Scholar Back to article
Astrup A Rössner S Van Gaal L NN8022-1807 Study Group Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 2009 Nov 7 374 9701 1606 16
Search in Google Scholar Back to article
Astrup A Carraro R Finer N Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide Int J Obes (Lond) 2012 Jun 36 6 843 54
Search in Google Scholar Back to article
Zinman B Wanner C Lachin J Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes N Engl J Med 2015 Nov 26 373 22 2117 28
Search in Google Scholar Back to article
Neal B Perkovic V Mahaffey K CANVAS Program Collaborative Group Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes N Engl J Med 2017 Aug 17 377 7 644 57
Search in Google Scholar Back to article
Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2012–2018 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58); 2012 Nov 21 [cited 2018 Jul 2]. Available from: https://clinicaltrials.gov/ct2/show/NCt101730534
Search in Google Scholar Back to article
Bhartia M Tahrani A Barnett A SGLT-2 inhibitors in development for type 2 diabetes treatment Rev Diabet Stud 2011 Fall 8 3 348 54
Search in Google Scholar Back to article
Ruanpeng D Ungprasert P Sangtian J Harindhanavudhi T Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis Diabetes Metab Res Rev 2017 Sep 33 6
Search in Google Scholar Back to article
Standards of Medical Care in Diabetes-2018 Diabetes Care 2018 Jan 41 S1 S73 85
Search in Google Scholar Back to article
Garber AJ Abrahamson MJ Barzilay JI Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary Endocr Pract 2018 Jan 24 1 91 120
Search in Google Scholar Back to article
Kim H Park S Ko S Committee of Clinical Practice Guidelines of the Korean Diabetes Association Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association Diabetes Metab J 2017 Dec 41 6 423 9
Search in Google Scholar Back to article
Inzucchi S Bergenstal R Buse J Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 Jan 38 1 140 9
Search in Google Scholar Back to article
GoodRx [Internet] Santa Monica, CA GoodRx, Inc. c2018 [cited 2018 Jul 2]. Available from: https://www.goodrx.com
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.14797/mdcj-14-4-281 | Journal eISSN: 1947-6108

Journal RSS Feed

Language: English

Page range: 281 - 288

Published on: Oct 1, 2018

Published by: Houston Methodist DeBakey Heart & Vascular Center

In partnership with: Paradigm Publishing Services

Keywords:

incretins,

GLP-1 RA,

DPP-4,

SGLT2,

cardiovascular disease,

heart failure,

myocardial infarction,

type 2 diabetes

© 2018 Ahmad Yehya, Archana R. Sadhu, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 14 (2018): Issue 4